{"id":"r-mp-and-procarbazine-maintenance","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1321","moleculeType":"Small molecule","molecularWeight":"221.30"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"R-MP is a chemotherapy medication that interferes with DNA replication and transcription, causing DNA damage and inhibiting cancer cell growth. Procarbazine is a chemotherapy medication that works by inhibiting DNA repair mechanisms, making cancer cells more susceptible to DNA damage. Together, they create a synergistic effect that enhances their individual anticancer activities.","oneSentence":"R-MP and Procarbazine work together to target and kill cancer cells through a combination of DNA damage and inhibition of DNA repair.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:48.476Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance therapy in patients with anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT06830421","phase":"PHASE3","title":"Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients","status":"RECRUITING","sponsor":"University Hospital Freiburg","startDate":"2023-08-09","conditions":"Primary Central Nervous System Lymphoma","enrollment":340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-MP and Procarbazine maintenance","genericName":"R-MP and Procarbazine maintenance","companyName":"University Hospital Freiburg","companyId":"university-hospital-freiburg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-MP and Procarbazine work together to target and kill cancer cells through a combination of DNA damage and inhibition of DNA repair. Used for Maintenance therapy in patients with anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}